Respiratory

Gut microbiota composition may influence the efficacy and safety of chemo-immunotherapy in advanced non-small cell lung cancer.

A Phase IV trial has demonstrated that dupilumab significantly reduces airway inflammation in patients with uncontrolled, moderate-to-severe type 2 asthma.

Interim findings from the ongoing SOTERIA study suggest that sotatercept provides a favourable long-term safety and efficacy profile for adults with pulmonary arterial hypertension.

A new study assessed asthma risk in children who received antibiotics in the first week of life solely due to maternal indications, eliminating infection-related bias.

A large-scale study suggests that pirfenidone use in patients with idiopathic pulmonary fibrosis may be linked to a lower incidence of lung cancer.

Individuals with impaired lung function trajectories experience a higher burden of respiratory symptoms, including wheeze and phlegm.

The UK IPF Registry has provided new insights into the evolving landscape of idiopathic pulmonary fibrosis management, showing significant shifts in diagnosis and treatment approaches over the last decade.

Lung cancer screening presents a crucial opportunity to address tobacco dependence, as participation is associated with increased motivation to quit smoking.